NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Aegis Therapeutics, LLC

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Aegis Therapeutics to Present at the 4th Annual Peptide Therapeutics Symposium November 17–18 - Aegis Therapeutics presents recent developments in non-invasive drug delivery options for peptide and protein drugs circumventing the need for injections - PeptideTherapeutics.org
Aegis Therapeutics to Present at the 4th Annual Peptide Therapeutics Symposium November 17–18

 

NewswireTODAY - /newswire/ - San Diego, CA, United States, 2009/09/11 - Aegis Therapeutics presents recent developments in non-invasive drug delivery options for peptide and protein drugs circumventing the need for injections - PeptideTherapeutics.org.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In a talk entitled: “Non-Invasive Systemic Delivery of Peptides with High Bioavailability”, Dr. Edward Maggio, CEO of Aegis Therapeutics will present recent developments in highly efficient systemic delivery of peptide therapeutics through various transmucosal routes including oral, nasal, and buccal/sublingual administration, at the 4th Annual Peptide Therapeutics Symposium to be held at The Salk Institute for Biological Sciences, San Diego, on November 17 – 18, 2009.

The symposium, sponsored by the Peptide Therapeutics Foundation (peptidetherapeutics.org), brings together world leaders in peptide research from academia and the biopharmaceutical industry and will present the most recent and exciting developments in the peptide field. The scientific program will focus on novel peptide strategies to address cell surface and intracellular targets, and non-parenteral peptide drug delivery. The keynote address will be given this year by Professor Roger Tsien, 2008 Nobel Laureate for Chemistry. The full program for the meeting may be viewed online.

About Aegis Therapeutics

Aegis Therapeutics, LLC (aegisthera.com) is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our patented Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics via the intranasal administration route with exceptionally high and unmatched bioavailability that can currently only be achieved by injection. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our patented ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Aegis Therapeutics, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Aegis Therapeutics to Present at the 4th Annual Peptide Therapeutics Symposium November 17–18

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Edward Maggio, PhD - AegisThera.com 
858-618-1400 rbarry[.]aegisthera.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Aegis Therapeutics, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Aegis Therapeutics, LLC / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing
STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award
BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™
BASF Invests in Start-up 3Helix, Inc. to Jointly Bring Collagen-hybridizing Peptide Solutions to the Personal Care Market
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Thales and Bertin Partner in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN
Ipsen Updates on E.U. Marketing Authorisation Application for Odevixibat in Alagille Syndrome
BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform
NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)